Glutaric acidemia type 1 (clinical cases)
Authors:
- Оксана Валерьевна ГлобаОГОксана Валерьевна Глоба
- Lyudmila M. KuzenkovaLKLyudmila M. Kuzenkova
- Tatiana V. BushuevaTBTatiana V. Bushueva
- Aleksander A. PushkovAPAleksander A. Pushkov
- Kirill V. Savost’yAnovKSKirill V. Savost’yAnov
- Anatoliy V. AnikinAAAnatoliy V. Anikin
- Olga I. ZyrianovaOZOlga I. Zyrianova
- Aleksander A. BukshABAleksander A. Buksh
- 30 June 2022
- journal article
- research article
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 3 (2) , 82-95
Abstract
Glutaric aciduria type 1 (glutaryl-CoA dehydrogenase deficiency, glutaric acidemia type 1) (OMIM 231670) is an autosomal recessive disease caused by mutations in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH). Glutaryl-CoA dehydrogenase (GCDH) plays an important role in the degradation metabolism of L-lysine, L-hydroxylysine and L-tryptophan. The insufficiency or absence of the enzyme leads to the accumulation of by-products of degradation of such amino acids as glutaric acid, 3-hydroxyglutaric acid, glutarylcarnitine (C5DC-acylcarnitine) and glutaconic acid. The accumulation of glutaric acid and 3-OH-glutaric acid causes neurotoxicity. Glutaric aciduria type 1 can manifest itself in early childhood with encephalitis-like crises: from three months to three years as GA-1 with infantile onset or from the age of six years as the late onset of GA-1. It is characterized by progressive neurological motor disorders, with the appearance of various types of hyperkinesis in combination with spasticity, a high incidence of disability and mortality. In about 25% of cases, the disease has a subacute course and manifests over the first year of life with a delay in psychomotor development, the gradual development of hyperkinetic syndrome, and spasticity. Awareness of doctors and alertness regarding diseases from the group of hereditary metabolic diseases will help to carry out therapy in a timely manner both in the acute period and in the appointment of long-term therapy to prevent disability of patients.Keywords
This publication has 23 references indexed in Scilit:
- Exome sequencing identifies GCDH (glutaryl-CoA dehydrogenase) mutations as a cause of a progressive form of early-onset generalized dystoniaHuman Genetics, 2011
- Diagnosis and management of glutaric aciduria type I – revised recommendationsJournal of Inherited Metabolic Disease, 2011
- Glutaric aciduria type 1 presenting with epilepsyDevelopmental Medicine & Child Neurology, 2009
- Classic and late‐onset neurological disease in two siblings with glutaryl‐CoA dehydrogenase deficiencyJournal of Inherited Metabolic Disease, 2007
- Natural History, Outcome, and Treatment Efficacy in Children and Adults with Glutaryl-CoA Dehydrogenase DeficiencyPediatric Research, 2006
- Crystal Structures of Human Glutaryl-CoA Dehydrogenase with and without an Alternate Substrate: Structural Bases of Dehydrogenation and Decarboxylation Reactions,Biochemistry, 2004
- Long-term follow-up, neurological outcome and survival rate in 28 Nordic patients with glutaric aciduria type 1European Journal of Paediatric Neurology, 2004
- Use of Tandem Mass Spectrometry for Multianalyte Screening of Dried Blood Specimens from NewbornsClinical Chemistry, 2003
- Mutation analysis in glutaric aciduria type IJournal of Medical Genetics, 2000
- A G-to-T transversion at the +5 position of intron 1 in the glutaryl CoA dehydrogenase gene is associated with the island Lake variant of glutaric acidemia type IHuman Molecular Genetics, 1995